untitled
|
|
|
- おきみち うすい
- 9 years ago
- Views:
Transcription
1
2
3
4
5
6 HBV HBV (1964) HDV (1977) HCV (1988)
7
8
9
10
11 2009
12
13
14
15
16
17
18
19 Yotsuyanagi H et al. J Med Virol 2005 Yotsuyanagi H et al. J Hepatol 2002
20
21 Universal vaccination (UV) 45 HB 2009
22
23
24
25 1/3
26
27
28
29
30 Progress Toward the Elimination of Hepatitis B Virus Transmission Among Health Care Workers in the United States Francis J. Mahoney, et al. Arch Intern Med. 1997;157(22): employees (90%) were eligible to receive hepatitis B vaccine, and 66.5% of them (95% confidence interval, 61.9%- 70.9%) had received 3 doses of hepatitis B vaccine. Studies on long-term protection demonstrate that vaccine induced protection persists at least 11 years even when titers of antibody to hepatitis B surface antigen decline below detectable levels.
31 10
32
33
34
35
36
37 HBV HBV HIV 1.7RNA 4.3
38 2008
39
40
41
42
43
44
45 HBV+HCV 7.3% ( ) 63% 6.3% HBV 19.6% HCV 66.8% HBV:HBsAg(+) HCV:anti-HCV(+) n=842 K. Koike Univ. of Tokyo
46 HCV 1-6 months 20-30% 70-80% Rare 50% 15-30% 5-7%/ HCC F1: 0-1%/year y F2: 1-2%/year F3: 3-5%/year
47 2/3 NS3 protease inhibitors (Telaprevir, etc.) ) NS5B RNA polymerase inhibitors (R1626, R7128, VCH759, etc.) Ursodeoxycholic acid ( ) Glycyrrhizine ( C (iron depletion therapy)
48
49 100 (sus stained virologica al respo onse) IFN Peg-IFN IFN IFN IFN Peg-IFN RBV RBV RBV RBV IFN
50
51 15/19 44/64 99/168 p< /8 135/ /262 10/35 12/22 35/67 p< /184 65/242 5/28 Cochran-Armitage test
52 SVR. non-svr) (2009: analysis of 1598 cases from 29 institutes)
53
54
1) Garner J. S.: The Hospital Infection Control Practices Advisory Committee, CDC, Guidelines for Isolation Precautions in Hospitals, 1996. http://wonder.cdc.gov/wonder/prevguid/ p0000419/p0000419.asp.
! 1Munderl P et al. Survival and causes of death, 2 years after Introduction of antiretroviral therapy in Africa. XVI International AIDS Conference, 2006, Abstract THLB0208. 2Walensky RP et al. The
表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
untitled
1988 2000 2002 2004 2006 2008 IFN Lamivudine Adefovir Entecavir 1 Total number 560 Sex (male/female) 424/136 Age (years)* 38 (15-68) Duration of treatment (weeks)* 26 (1-592) Follow-up time (years) 75(05-21
28 1 1a 1b 2 MRI T2 3 CT C3 N95 N95 6ml 90
2015 28 1 89 93 CT C3 Tb PCR XP WBC 7 600/mm 3 CRP 4 08mg/dl MRI MRI CT MRI WBC 9 700/mm 3 CRP 6 09mg/dl CT C3 C2 C7 low density area CT 89 28 1 1a 1b 2 MRI T2 3 CT C3 N95 N95 6ml 90 28 1 4 CT C2 C7 low
Establishment and progress of Sendai virus engineering 2) Schnell, M. J., Mebatsion, T., Conzelmann, K.-K.: EMBO J., 13,4195-4203(1994) 3) Kato, A. et al.: Genes Cells, 1, 569-579 (1996) 4) Nagai,
11.修正_プレゼン資料（鹿児島大学_池田先生）0711
従来の薬剤探索法では 見出すことができなかった 新規抗 HCV 剤グアンファシンの同定 鹿児島大学大学院医歯学総合研究科難治ウイルス病態制御研究センターセンター長池田正徳 従来技術とその問題点 C 型肝炎ウイルス (HCV) に感受性のある唯一動物モデルはチンパンジーのみであるが 霊長類であるチンパンジーを使った研究は現在 倫理的経済的問題からなされていない 現在 すべての抗 HCV 剤は 唯一 HCV
276-E12001.indd
2012; 54 (6): 276 285 91.6% 1 1 91.6% 2 142 54 196 (1) (2) 6 (3) (4) 60 1 54.2% 91.6% 1 6,226,192 8,418,514 65,945 300,898 ROI 933% 2012; 54 (6): 276 285 doi: 10.1539/sangyoeisei.E12001 1,2) 2) 3) 3 5)
明浄創立１０周年記念号／６．佐伯
10 6 1 21 2 5 7 35 1 S 1 1 90 19 475 60 402 18 82 69.2 71.6 68.8 2 2008 5 7 30 10 1 13 WHO 6 4 4 1, 3, 6, 10 2, 9, 124, 5, 78, 11, 13 1 1 2 3 4 5 6 7 8 9 10 11 12 13 1 1 2 2 3 3 4 4 3 4 1 4 4 2 10 10 3
fpj
Folia Pharmacol. Jpn. 145 C 天野 学 1), 石川博樹 2) 要約 : genotype C C IFN C HCV A NS A NS / A NS / AHCV in vitro HCV genotype genotype HCV HCV Genotype b C mg mg IL B IFN IFN 1. はじめに C HCV, HCV HCV HCV, C HCV.
IU/mL.1 IU/mL A , % % 6.% 7 B %.1 IU/mL IU/mL % %.1 IU/mL % 7/9 4
7 1,315 213 KPA.1 IU/mL 21 9% 22 44 75%.1 IU/mL 1975 DPT 45 49 39.7% 5 22.1% Clostridium tetani 1 21 213 4 16 118 118 128 1948 1952 1959 1964 DPT 1968 1975 2 1 4 DPT 1981 DTaP212 DPT-IPV 7 7 1,315 1 2
ON A FEW INFLUENCES OF THE DENTAL CARIES IN THE ELEMENTARY SCHOOL PUPIL BY Teruko KASAKURA, Naonobu IWAI, Sachio TAKADA Department of Hygiene, Nippon Dental College (Director: Prof. T. Niwa) The relationship
VERO IU/mL.1 IU/mL A , % % 6.% 7 B %.1 IU/mL IU/mL %.1 IU/mL 1
7 1,348 213 VERO.1 IU/mL 1 82.8% 1 5 9%.1 IU/mL 1 6 9 58.7% 1 46.2% 12 15 8%.1 IU/mL 2 3-34 7% 36.9%1975 DPT 4 54 5% 55 1958 12.9%.1 IU/mL Corynebacterium diphtheriae 1999 1948 1958 DP 1964 DPT 1968 1975
理学療法検査技術習得に向けた客観的臨床能力試験(OSCE)の試行
An Application of an Objective Structured Clinical Examination for Learning Skills in Assessment of Physical Therapy A Task Involving Measurements on the Range of Motion Test Chikako Fujita1) Hiroyasu
Ｈｕｍａｎ Ｗｅｌｆａｒｅ ８‐１☆／４．坂口
1 2 1914 2007 2002 2013 2004 2013 2009 2011 5 1 2 Human Welfare 8 1 2016 1 110 2014 9 11 11 8 110 4 106 3 2.8 103 97.2 18 76 37.4 SD 16.5 2 1 1 3 2 10 65 2006 65 25 4 5 1 5 3 98 4 60 60 4 1 4 1 60 15.1
/‚“1/ŒxŒ{‚×›î’æ’¶
60 1 pp.3-8 2010 1. H1N1 1) 2) 3) 4) ERATO 2009 H1N1 21 H1N1 HA PB2 2009 3 Pandemic H1N1 2009 WHO 6 11 21 2009 11 2010 4 21 H1N1 H1N1 2009 4 15 CDC 108-8639 4-6-1 TEL: 03-5449-5281 FAX: 03-5449-5408 E-mail:
特集・総説・報告（４４行）／Ｐ０４５－０５５＿報告 日本肝移植研究会
45 Liver Transplantation in Japan in 2006 Part 2 Registry by the The Summary Four thousand three hundred thirty liver transplants have been performed as of December 31, 2006 in 59 institutions in Japan.
Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo
Kekkaku Vol. 79, No. 1: 17-24, 2004 17 (Received 21 Aug. 2003/Accepted 18 Nov. 2003) Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly
DDWシェリング講演スライド（２００９年１０月）
ウイルス肝炎治療の現状と 治療薬開発の方向性 関西労災病院病院長林紀夫 B 型肝炎 HBV キャリアの臨床経過 HBV 感染 ( 垂直感染, 乳幼児水平感染 ) < 10% ウイルス排除 / 治癒 急性増悪肝不全 2000 人 /year キャリア化 90% HBe 抗原陽性無症候性キャリア 慢性肝炎 2%/year 肝硬変 85-90% 0.8% 再活性化 /year 10% 4% /year HBe
Table 1 Characteristics of the study participants in Imari municipal hospital
Key words: tuberculosis, booster phenomenon, two-step tuberculin test Table 1 Characteristics of the study participants in Imari municipal hospital Fig. 1 Frequency distributions of size of the first tuberculin
Microsoft PowerPoint - 4. 資料２．泉先生スライド.ppt [互換モード]
![Microsoft PowerPoint - 4. 資料２．泉先生スライド.ppt [互換モード]](/thumbs/97/130983871.jpg "Microsoft PowerPoint - 4. 資料２．泉先生スライド.ppt [互換モード]")
第 14 回肝炎治療戦略会議 215.5.18 ゲノタイプ 2 型に対するソホスブビル + リバビリンによる 12 週間の治療 武蔵野赤十字病院消化器科 泉並木 1 C 型肝炎からの発癌と肝線維化 8 武蔵野赤十字病院 n=1746 Stage 4 Cumulative incidence of HCC (%) 6 4 2 26% 19% 57% 42% 23% n=157 n=425 n=533
女子短大生に対する栄養マネジメント教育とその評価
10 11 12 http://www.center.ibk.ed.jp/contents/kenkyuu /houkoku/data/030s/sport1.htm http://www.mhlw.go.jp/bunya/kenkou/eiy ou/dl/h24-houkoku.pdf http://www.mhlw.go.jp/bunya/kenkou/dl/ kenkounippon21_02.pdf
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
N 847 1085 1932 2966 3336 6302 % 43.8 56.2 100 47.1 52.9 100 28 72 41.34 28 77 51.52 N 84 750 580 478 28 12 1932 % 4.3 38.8 30.0 24.7 1.4 0.6 100 N 1079 2710 1318 1083 60 52 6302 % 17.1 43.0 20.9 17.2
Ł\”ƒ1PDFŠp
48 2006 21 36 Koya KISHIDA, Shuji HISAMUNE, Toshihiko OSHIMA and Akira TAKEI Recently, when the accident occurs, the social influences of the accident became more and more severe. Keifuku Electric Railroad
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc
A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, School of Medicine, Tokushima University, Tokushima Fetal
C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection
Mix*: 2 bilateral Syme's amputation, 3 Syme's-B/K, 1 Syme's-A/K 1 bilateral through knee, 1 A/K through hip 2. Kegel, B., Carpenter, M. L. and Burgess, E. M.: Functional Capabilities of Lower Extremity
名称未設定-1
Study on Clinical Factors Affecting the Fungal Culture Test - Relevance of Dry Mouth - Yoshiko YAMAMURA, Yukihiro MOMOTA, Hideyuki TAKANO, Koichi KANI, Katsumi MOTEGI, Fumihiro MATSUMOTO, Masayuki AZUMA
2) Cohn, Jahrb. f. Khk., Bd. 37, S. 187, 1918. 3) Elgood, v. Korenchevsky, The aetiology and pathology of rickets from an experimental 11) Kassowitz, Jahrb. f. Khk., Bd. 65, S. 251, point of view, P. 155,
顔面神経麻痺を来したMPO―ANCA 陽性の中耳炎２症例
11367 : MPOANCA MPO ANCA MPOANCA 134EU MPO ANCA 67EU MPOANCA ANCA : MPOANCAANCA antineutrophil cytoplasmic antibody ; ANCA Davies IgG ANCA PR3proteinase3ANCA MPOmyeloperoxidaseANCA Wegener PR3ANCA MPO
pp 427 438 2006 Dimensional Change Card Sort ****** ** 2005 9 30 2004 8 2002 4 Zelazo, P. D., Carter, A., Reznick, J. S. & Frye, D. 1997 10 2003 Zelaz
Title 幼 児 の 実 行 機 能 の 発 達 過 程 : Dimensional Change C を 用 いたルールの 理 解 とその 使 用 に 関 する 検 討 Author(s) 浮 穴, 寿 香 ; 橋 本, 創 一 ; 出 口, 利 定 Citation 東 京 学 芸 大 学 紀 要. 総 合 教 育 科 学 系, 57: 427-438 Issue Date 2006-02-00
untitled
2005 10 13 Dr. RGA 19602000 10 Australian Institute of of Health and and Welfare 2004 ABS Cat. Cat. No. No. 3201.0; AIHW National Population Database 1875 2 211997 8 122164 http://www.wowzone.com/calment.htm
Fig. 1 Photography of exercise test by Arm Crank Ergometer. Fig. 2 Photography of exercise test by chair with caster. Arm Crank Ergometer Wheelchair T
Fig. 1 Photography of exercise test by Arm Crank Ergometer. Fig. 2 Photography of exercise test by chair with caster. Arm Crank Ergometer Wheelchair Treadmill Arm Crank Ergometer Arm Crank Ergometer Arm
2 The Bulletin of Meiji University of Integrative Medicine 3, Yamashita 10 11
1-122013 1 2 1 2 20 2,000 2009 12 1 2 1,362 68.1 2009 1 1 9.5 1 2.2 3.6 0.82.9 1.0 0.2 2 4 3 1 2 4 3 Key words acupuncture and moxibustion Treatment with acupuncture, moxibustion and Anma-Massage-Shiatsu
Short Review Hidenori Takagi, Fumio Takaiwa, E-mail : [email protected] 13) Hirahara, K. et al. : J. Allergy Clin. Immunol., 102, 961-967 (1998) 14) Takagi, H. et al.: Proc. Natl. Acad. Sci.
2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
日本における結婚観の変化―JGSS累積データ を用いた分析―
JGSS 2000-2010 JGSS Changes in Attitudes toward Marriage in Japan: Analyses Using the JGSS Cumulative Data 2000-2010 Sayaka K. SHINOHARA JGSS Research Center Osaka University of Commerce Using the Japanese
長崎県県央保健所事業概要
P1 P2~P3 P4 P5 P7~P10 P11~P40 P41~P174 P175~P179 P181~P212 271,417 2 3 4 5 5 7 8 9 10 12 13 14 15 16 18 19 2,506 365 293 5 20 2 4 123 4 17 1 2 143 351 5 3 18 40 10 475 3 2 22 22 66 1 13 18 31 10
indd
24 61 1 2011 調査 研究 1 2 1 1 2 4 1 3 4 1 2 1 2 1 2 1 2 2 1 1 2 3 4 2010 11 11 2011 1 7 Infection Control in an Endoscopy Room Multi - society Guideline and Current Status at Fukushima Medical University
Arthroscopic Treatment for Painful Bennett Lesions of the Shoulder in Baseball Players by M. Yoneda and K. Hayashida Department of Orthopaedic Surgery
Arthroscopic Treatment for Painful Bennett Lesions of the Shoulder in Baseball Players by M. Yoneda and K. Hayashida Department of Orthopaedic Surgery, Osaka Kosei-Nenkin Hospital K. Izawa and S. Wakitani